2 patents currently held
10 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
5 more records may belong here and await a decision; they are not counted.
The next term ends in Feb 2030. from the record
Of the 10 now held by other companies, 8 name Amarin Pharmaceuticals Ireland Limited as their current owner, and 2 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
2
Ending by 2030
Feb 2030
Next term end
1
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 1 of the currently held patents qualifies as notable.
Formerly held, still cited
Notable
Ends Jul 2031 · High confidence
Cited by 144 later US patents, top 1% of utility patents granted in 2021 in our data. Protection runs to 2031.
now held by Amarin Pharmaceuticals Ireland Limited
Also notable
Ends Oct 2030 · High confidence
The most cited patent in this portfolio, cited by 266 later US patents, top 5% of utility patents granted in 2012 in our data. Protection runs to 2030.
now held by Amarin Pharmaceuticals Ireland Limited
Also notable
Ends no later than Dec 2030 · Medium confidence
Cited by 233 later US patents, top 5% of utility patents granted in 2013 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2030. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
now held by Amarin Pharmaceuticals Ireland Limited
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Feb 1, 2027
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Showing 1 to 2 of 2
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,712,428 | Low Eructation Composition and Methods for Treating And/Or Preventing Cardiovascular Disease in a Subject with Fish Allergy/Hypersensitivity In force · Medium confidence | In force | Medium confidence | |
| US 11,712,429 | Low Eructation Composition and Methods for Treating And/Or Preventing Cardiovascular Disease in a Subject with Fish Allergy/Hypersensitivity In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 2: 10 patents in force now held by others · 13 patents ended · 31 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
5 terminal disclaimers are on file with no resolved reference. No cap is applied and none is guessed